نتائج البحث - "Gil, Miguel J."

1

دورية أكاديمية

Impact of coadministration of proton-pump inhibitors and palbociclib in hormone receptor-positive/HER2-negative advanced breast cancer

المؤلفون: Pérez-García, José Manuel, dalenc, florence, Ruiz-Borrego, Manuel, Di Cosimo, Serena, Bellet Ezquerra, Meritxell, Gil Gil, Miguel J.

المساهمون: Institut Català de la Salut, Di Cosimo S Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy. Medica Scientia Innovation Research (MEDSIR), Barcelona, Spain and Ridgewood, NJ, United States. Pérez-García JM Medica Scientia Innovation Research (MEDSIR), Barcelona, Spain and Ridgewood, NJ, United States. International Breast Cancer Center (IBCC), Pangaea Oncology, Quirón Group, Barcelona, Spain. Bellet M Servei d’Oncologia Mèdica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Dalenc F Oncopole Claudius Regaud-IUCT, CRCT, Inserm, Department of Medical Oncology, Toulouse, France. Gil Gil MJ Institut Català d'Oncologia, Breast Cancer Unit and Medical Oncology Department, IDIBELL, L'Hospitalet, Barcelona, Spain. Ruiz-Borrego M Hospital Universitario Virgen del Rocío, Medical Oncology Department, Seville, Spain, Vall d'Hebron Barcelona Hospital Campus

المصدر: Scientia

مصطلحات موضوعية: Mama - Càncer - Tractament, Medicaments antiulcerosos - Ús terapèutic, Proteïnes quinases - Inhibidors - Ús terapèutic, DISEASES::Neoplasms::Neoplasms by Site::Breast Neoplasms, Other subheadings::Other subheadings::Other subheadings::/drug therapy, CHEMICALS AND DRUGS::Chemical Actions and Uses::Pharmacologic Actions::Molecular Mechanisms of Pharmacological Action::Enzyme Inhibitors::Proton Pump Inhibitors, CHEMICALS AND DRUGS::Chemical Actions and Uses::Pharmacologic Actions::Molecular Mechanisms of Pharmacological Action::Enzyme Inhibitors::Protein Kinase Inhibitors, ENFERMEDADES::neoplasias::neoplasias por localización::neoplasias de la mama, Otros calificadores::Otros calificadores::Otros calificadores::/farmacoterapia, COMPUESTOS QUÍMICOS Y DROGAS::acciones y usos químicos::acciones farmacológicas::mecanismos moleculares de acción farmacológica::inhibidores enzimáticos::inhibidores de la bomba de protones, COMPUESTOS QUÍMICOS Y DROGAS::acciones y usos químicos::acciones farmacológicas::mecanismos moleculares de acción farmacológica::inhibidores enzimáticos::inhibidores de proteínas cinasas

وصف الملف: application/pdf

العلاقة: The Breast;76; https://doi.org/10.1016Test/j.breast.2024.103761; Di Cosimo S, Pérez-García JM, Bellet M, Dalenc F, Gil Gil MJ, Ruiz-Borrego M, et al. Impact of coadministration of proton-pump inhibitors and palbociclib in hormone receptor-positive/HER2-negative advanced breast cancer. The Breast. 2024 Jun 11;76:103761.; https://hdl.handle.net/11351/11607Test

الإتاحة: https://doi.org/10.1016Test/j.breast.2024.103761
https://hdl.handle.net/11351/11607Test

View record in BASE

النص الكامل

2

دورية أكاديمية

Observational study of HR+/HER2− metastatic breast cancer patients treated with abemaciclib in Spain in the Named Patient Use Program (AbemusS)

المؤلفون: Blanch, Salvador, Gil Gil, Miguel J., Arumí De Dios, Míriam, SEGUI PALMER, MIQUEL ANGEL, Atienza, Manuel, AGUIRRE, ELENA

المساهمون: Institut Català de la Salut, Blanch S Instituto Valenciano de Oncología (IVO), Carrer del Professor Beltrán Báguena, Valencia, Spain. Gil-Gil JM Institut Català d’Oncologia (ICO), Barcelona, Spain. Arumí M Servei d’Oncologia Mèdica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Aguirre E Hospital Universitario Miguel Servet, Zaragoza, Spain. Seguí MÁ Hospital Parc Taulí de Sabadell, Sabadell, Barcelona, Spain. Atienza M Medical Department, Lilly Spain, Madrid, Spain, Vall d'Hebron Barcelona Hospital Campus

المصدر: Scientia

مصطلحات موضوعية: Avaluació de resultats (Assistència sanitària), Mama - Càncer - Tractament, Medicaments antineoplàstics - Ús terapèutic, DISEASES::Neoplasms::Neoplasms by Site::Breast Neoplasms, Other subheadings::Other subheadings::Other subheadings::/drug therapy, CHEMICALS AND DRUGS::Chemical Actions and Uses::Pharmacologic Actions::Therapeutic Uses::Antineoplastic Agents, Other subheadings::Other subheadings::/therapeutic use, ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Diagnosis::Prognosis::Treatment Outcome, ENFERMEDADES::neoplasias::neoplasias por localización::neoplasias de la mama, Otros calificadores::Otros calificadores::Otros calificadores::/farmacoterapia, COMPUESTOS QUÍMICOS Y DROGAS::acciones y usos químicos::acciones farmacológicas::usos terapéuticos::antineoplásicos, Otros calificadores::Otros calificadores::/uso terapéutico, TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::diagnóstico::pronóstico::resultado del tratamiento

وصف الملف: application/pdf

العلاقة: Clinical and Translational Oncology;25; https://doi.org/10.1007/s12094-023-03159-9Test; Blanch S, Gil-Gil JM, Arumí M, Aguirre E, Seguí MÁ, Atienza M, et al. Observational study of HR+/HER2− metastatic breast cancer patients treated with abemaciclib in Spain in the Named Patient Use Program (AbemusS). Clin Transl Oncol. 2023 Oct;25:2950–59.; https://hdl.handle.net/11351/10252Test; 000964093800001

الإتاحة: https://doi.org/10.1007/s12094-023-03159-9Test
https://hdl.handle.net/11351/10252Test

View record in BASE

3

دورية أكاديمية

Palbociclib with Fulvestrant or Letrozole in Endocrine-Sensitive Patients with HR-Positive/HER2-Negative Advanced Breast Cancer: A Detailed Safety Analysis of the Randomized PARSIFAL Trial

المؤلفون: Pérez-García, José Manuel, Dalenc, Florence, Gil-Gil, Miguel J., Ruiz Borrego, Manuel, Di Cosimo, Serena, Bellet Ezquerra, Meritxell

المساهمون: Institut Català de la Salut, Di Cosimo S ndazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy. Medica Scientia Innovation Research (MEDSIR), Barcelona, Spain. Medica Scientia Innovation Research (MEDSIR), Ridgewood, NJ, USA. Pérez-García JM International Breast Cancer Center (IBCC), Quironsalud Group, Barcelona, Spain. Medica Scientia Innovation Research (MEDSIR), Barcelona, Spain. Medica Scientia Innovation Research (MEDSIR), Ridgewood, NJ, USA. Bellet M Servei d’Oncologia Mèdica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Dalenc F Institut Claudius Regaud, IUCT-Oncopole, CRCT, Inserm, Department of Medical Oncology, Toulouse, France. Gil Gil MJ Institut Català d’Oncologia, Breast Cancer Unit and Medical Oncology Department, IDIBELL, L’Hospitalet, Barcelona, Spain. Ruiz Borrego M Hospital Universitario Virgen del Rocío, Medical Oncology Department, Seville, Spain, Vall d'Hebron Barcelona Hospital Campus

المصدر: Scientia

مصطلحات موضوعية: Mama - Càncer - Tractament, Quimioteràpia combinada, DISEASES::Neoplasms::Neoplasms by Site::Breast Neoplasms, Other subheadings::Other subheadings::Other subheadings::/drug therapy, ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Therapeutics::Therapeutics::Drug Therapy::Antineoplastic Protocols::Therapeutics::Drug Therapy::Antineoplastic Combined Chemotherapy Protocols, Other subheadings::Other subheadings::/therapeutic use, ENFERMEDADES::neoplasias::neoplasias por localización::neoplasias de la mama, Otros calificadores::Otros calificadores::Otros calificadores::/farmacoterapia, TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::terapéutica::terapéutica::farmacoterapia::protocolos antineoplásicos::terapéutica::farmacoterapia::protocolos de quimioterapia antineoplásica combinada, Otros calificadores::Otros calificadores::/uso terapéutico

وصف الملف: application/pdf

العلاقة: The Oncologist;28(1); https://doi.org/10.1093/oncolo/oyac205Test; Di Cosimo S, Pérez-García JM, Bellet M, Dalenc F, Gil Gil MJ, Ruiz Borrego M, et al. Palbociclib with Fulvestrant or Letrozole in Endocrine-Sensitive Patients with HR-Positive/HER2-Negative Advanced Breast Cancer: A Detailed Safety Analysis of the Randomized PARSIFAL Trial. Oncologist. 2023 Jan;28(1):23-32.; https://hdl.handle.net/11351/8984Test; 000867852300001

الإتاحة: https://doi.org/10.1093/oncolo/oyac205Test
https://hdl.handle.net/11351/8984Test

View record in BASE

النص الكامل

4

دورية أكاديمية

Palbociclib Rechallenge for Hormone Receptor-Positive/HER-Negative Advanced Breast Cancer: Findings from the Phase II BioPER Trial

المؤلفون: Albanell, Joan, Pérez-García, José Manuel, Gil-Gil, Miguel J., Curigliano, Giuseppe, Ruiz Borrego, Manuel, Comerma Blesa, Laura, Bellet Ezquerra, Meritxell

المساهمون: Institut Català de la Salut, Albanell J Medical Oncology Department, Hospital del Mar, Barcelona, Spain. Cancer Research Program, IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain. Centro de Investigacion Biomédica en Red de Oncología (CIBERONC-ISCIII), Madrid, Spain. Universitat Pompeu Fabra, Barcelona, Spain. GEICAM, Spain. Pérez-García JM International Breast Cancer Center (IBCC), Quironsalud Group, Barcelona, Spain. Medica Scientia Innovation Research (MEDSIR), Barcelona, Spain and Ridgewood, New Jersey. Gil-Gil M GEICAM, Spain. Catalan Institute of Oncology, Breast Cancer Unit, Medical Oncology Department, IDIBELL, Barcelona, Spain. Curigliano G Istituto Europeo di Oncologia, IRCCS, Milano, Italy. University of Milano, Department of Oncology and Hemato-Oncology, Milano, Italy. Ruíz-Borrego M GEICAM, Spain. Hospital Universitario Virgen del Rocío, Sevilla, Spain. Comerma L Cancer Research Program, IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain. Pathology Department, Hospital del Mar, Barcelona, Spain. Bellet M Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain, Vall d'Hebron Barcelona Hospital Campus

المصدر: Scientia

مصطلحات موضوعية: Mama - Càncer - Tractament, Medicaments antineoplàstics - Ús terapèutic, DISEASES::Neoplasms::Neoplasms by Site::Breast Neoplasms, Other subheadings::Other subheadings::Other subheadings::/drug therapy, ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Therapeutics::Therapeutics::Drug Therapy::Antineoplastic Protocols::Therapeutics::Drug Therapy::Antineoplastic Combined Chemotherapy Protocols, ENFERMEDADES::neoplasias::neoplasias por localización::neoplasias de la mama, Otros calificadores::Otros calificadores::Otros calificadores::/farmacoterapia, TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::terapéutica::terapéutica::farmacoterapia::protocolos antineoplásicos::terapéutica::farmacoterapia::protocolos de quimioterapia antineoplásica combinada

وصف الملف: application/pdf

العلاقة: Clinical Cancer Research;29(1); https://doi.org/10.1158/1078-0432.CCR-22-1281Test; Albanell J, Pérez-García JM, Gil-Gil M, Curigliano G, Ruíz-Borrego M, Comerma L, et al. Palbociclib Rechallenge for Hormone Receptor-Positive/HER-Negative Advanced Breast Cancer: Findings from the Phase II BioPER Trial. Clin Cancer Res. 2023 Jan 4;29(1):67–80.; https://hdl.handle.net/11351/9405Test; 000908868900001

الإتاحة: https://doi.org/10.1158/1078-0432.CCR-22-1281Test
https://hdl.handle.net/11351/9405Test

View record in BASE

النص الكامل

5

دورية أكاديمية

Palbociclib with Fulvestrant or Letrozole in Endocrine-Sensitive Patients with HR-Positive/HER2-Negative Advanced Breast Cancer: A Detailed Safety Analysis of the Randomized PARSIFAL Trial.

مصطلحات موضوعية: advanced breast cancer, endocrine therapy, interstitial lung disease, neutropenia, palbociclib, pneumonitis, venous thromboembolism, Female, Humans, Antineoplastic Combined Chemotherapy Protocols, Breast Neoplasms, Fulvestrant, Letrozole, Pulmonary Embolism, Receptor, ErbB-2, Receptors, Estrogen

وصف الملف: application/pdf

العلاقة: http://hdl.handle.net/10668/19828Test; PMC9847524; https://academic.oup.com/oncolo/article-pdf/28/1/23/48837357/oyac205.pdfTest; https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9847524/pdfTest

الإتاحة: https://doi.org/10.1093/oncolo/oyac205Test
http://hdl.handle.net/10668/19828Test
https://academic.oup.com/oncolo/article-pdf/28/1/23/48837357/oyac205.pdfTest
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9847524/pdfTest

View record in BASE

النص الكامل

6

دورية أكاديمية

Infigratinib in Patients with Recurrent Gliomas and FGFR Alterations: A Multicenter Phase II Study

المصدر: Lassman, Andrew B; Sepúlveda-Sánchez, Juan Manuel; Cloughesy, Timothy F; Gil-Gil, Miguel J; Puduvalli, Vinay K; Raizer, Jeffrey J; De Vos, Filip Y F; Wen, Patrick Y; Butowski, Nicholas A; Clement, Paul M J; Groves, Morris D; Belda-Iniesta, Cristóbal; Giglio, Pierre; Soifer, Harris S; Rowsey, Steven; Xu, Cindy; Avogadri, Francesca; Wei, Ge; Moran, Susan; Roth, Patrick (2022). Infigratinib in Patients with Recurrent Gliomas and FGFR Alterations: A Multicenter Phase II Study. Clinical Cancer Research, 28(11):2270-2277.

مصطلحات موضوعية: Clinic for Neurology, 610 Medicine & health, Cancer Research, Oncology

وصف الملف: application/pdf

العلاقة: https://www.zora.uzh.ch/id/eprint/230044/1/ZORA_2270.pdfTest; https://www.zora.uzh.ch/id/eprint/230044/10/Lassman_et_al_Infigratinib_ZORA.pdfTest; info:pmid/35344029; urn:issn:1078-0432

الإتاحة: https://doi.org/10.5167/uzh-23004410.1158/1078-0432.ccr-21-2664Test
https://www.zora.uzh.ch/id/eprint/230044Test/
https://www.zora.uzh.ch/id/eprint/230044/1/ZORA_2270.pdfTest
https://www.zora.uzh.ch/id/eprint/230044/10/Lassman_et_al_Infigratinib_ZORA.pdfTest

View record in BASE

النص الكامل

7

دورية أكاديمية

Palbociclib with Fulvestrant or Letrozole in Endocrine-Sensitive Patients with HR-Positive/HER2-Negative Advanced Breast Cancer: A Detailed Safety Analysis of the Randomized PARSIFAL Trial

المساهمون: Pfizer

المصدر: The Oncologist ; volume 28, issue 1, page 23-32 ; ISSN 1083-7159 1549-490X

مصطلحات موضوعية: Cancer Research, Oncology

الإتاحة: https://doi.org/10.1093/oncolo/oyac205Test
https://academic.oup.com/oncolo/article-pdf/28/1/23/50064983/oyac205.pdfTest

View record in BASE

8

دورية أكاديمية

Long-Term Cardiac Safety and Survival Outcomes of Neoadjuvant Pegylated Liposomal Doxorubicin in Elderly Patients or Prone to Cardiotoxicity and Triple Negative Breast Cancer. Final Results of the Multicentre Phase II CAPRICE Study

المؤلفون: Gil-Gil, Miguel J., Bergamino, Milana, Barnadas, Agustí, Manso, Luis, Bellet Ezquerra, Meritxell, Saura Manich, Cristina, Morales, Serafin

المساهمون: Institut Català de la Salut, Gil-Gil MJ, Bergamino M Department of Medical Oncology, Institut Català d’Oncologia, IDIBELL, L’Hospitalet, Spain. Bellet M, Saura C Servei d’Oncologia Mèdica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Morales S Department of Medical Oncology, Hospital Arnau de Vilanova, Lleida, Spain. Barnadas A Department of Medical Oncology, Hospital de Sant Pau, Barcelona, Spain. Manso L Department of Medical Oncology, Hospital 12 de Octubre, Madrid, Spain, Vall d'Hebron Barcelona Hospital Campus

المصدر: Scientia

مصطلحات موضوعية: Mama - Càncer - Quimioteràpia, Avaluació de resultats (Assistència sanitària), Persones grans, ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Therapeutics::Combined Modality Therapy::Neoadjuvant Therapy, DISEASES::Neoplasms::Neoplasms by Site::Breast Neoplasms, Other subheadings::Other subheadings::Other subheadings::/drug therapy, AND EQUIPMENT::Diagnosis::Prognosis::Treatment Outcome::Progression-Free Survival, TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::terapéutica::tratamiento combinado::tratamiento neoadyuvante, ENFERMEDADES::neoplasias::neoplasias por localización::neoplasias de la mama, Otros calificadores::Otros calificadores::Otros calificadores::/farmacoterapia, DIAGNÓSTICOS Y TERAPÉUTICOS::diagnóstico::pronóstico::resultado del tratamiento::supervivencia libre de progresión

وصف الملف: application/pdf

العلاقة: Frontiers in Oncology;11; https://doi.org/10.3389/fonc.2021.645026Test; Gil-Gil MJ, Bellet M, Bergamino M, Morales S, Barnadas A, Manso L, et al. Long-Term Cardiac Safety and Survival Outcomes of Neoadjuvant Pegylated Liposomal Doxorubicin in Elderly Patients or Prone to Cardiotoxicity and Triple Negative Breast Cancer. Final Results of the Multicentre Phase II CAPRICE Study. Front Oncol. 2021 Jul;11:645026.; https://hdl.handle.net/11351/6949Test; 000677390600001

الإتاحة: https://doi.org/10.3389/fonc.2021.645026Test
https://hdl.handle.net/11351/6949Test

View record in BASE

النص الكامل